

Product Datasheet

TRAIL/TNFSF10 Antibody - BSA Free NB500-220

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 5

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB500-220

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB500-220



NB500-220

TRAIL/TNFSF10 Antibody - BSA Free



Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	36 kDa
Product Description	
Description	Novus Biologicals Rabbit TRAIL/TNFSF10 Antibody - BSA Free (NB500-220) is a polyclonal antibody validated for use in WB. Anti-TRAIL/TNFSF10 Antibody: Cited in 4 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	8743
Gene Symbol	TNFSF10
Species	Human, Mouse
Reactivity Notes	Human, Mouse reactivity reported in scientific literature (PMID: 1914164).
Specificity/Sensitivity	Reacts with residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.
Immunogen	residues [SNTLSSPNSKNE] of the N terminus of the TRAIL protein.
Product Application Details	
Applications	Western Blot
Recommended Dilutions	Western Blot 1:100-1:2000
Application Notes	<p>Western blot- Use at 1:500 to 1:1,000 dilution. However, the investigator should determine the optimal dilution for a specific application such as immunohistochemistry</p> <p>The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.</p>



Images

Effects of enolase 1, ubiquitin C, and iTS CM on the expression of tumor-promoting and tumor-suppressing genes. CM = conditioned medium, CN = control (no CM treatment), β -cat = β -catenin plasmids, siEno1 = Enolase 1 siRNA, siUbc = ubiquitin C siRNA, EO = EO771 mammary tumor cells. (A&B) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to enolase 1 and ubiquitin C in EO771 breast cancer cells. (C&D) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to β -catenin-overexpressing iTS CM impaired by siRNAs specific to enolase 1 and ubiquitin C. (E) Expression of PDL1 in EO771 mammary tumor cells in response to β -catenin-overexpressing iTS CM, enolase 1, and ubiquitin C. (F&G) Expression of MMP9, Runx2, Snail, p53, TRAIL, and caspase 3 in EO771 mammary tumor cells in response to β -catenin-overexpressing pre-treatment tumor cell-derived CM. (H) Low survival for cancer patients with a high transcript level of MMP9, Runx2, or Snail. (I) Proposed regulatory mechanism to inhibit tumor progression by iTS-CM. According to the mechanism, β -catenin-overexpressing iTS cells secrete ubiquitin C (Ubc), enolase 1 (Eno1), p53, and Trail. They suppress the progression of tumor cells by downregulating MMP9, Runx2, Snail, and PDL1, while upregulating cleaved-caspase 3. It should be noted that Eno1 interacts with CD44 and inhibits MMP9, Runx2, and Snail. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/34373756>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Effects of enolase 1, ubiquitin C, and iTS CM on the expression of tumor-promoting and tumor-suppressing genes. CM = conditioned medium, CN = control (no CM treatment), β -cat = β -catenin plasmids, siEno1 = Enolase 1 siRNA, siUbc = ubiquitin C siRNA, EO = EO771 mammary tumor cells. (A&B) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to enolase 1 and ubiquitin C in EO771 breast cancer cells. (C&D) Expression of MMP9, Runx2, Snail, p53, and TRAIL in response to β -catenin-overexpressing iTS CM impaired by siRNAs specific to enolase 1 and ubiquitin C. (E) Expression of PDL1 in EO771 mammary tumor cells in response to β -catenin-overexpressing iTS CM, enolase 1, and ubiquitin C. (F&G) Expression of MMP9, Runx2, Snail, p53, TRAIL, and caspase 3 in EO771 mammary tumor cells in response to β -catenin-overexpressing pre-treatment tumor cell-derived CM. (H) Low survival for cancer patients with a high transcript level of MMP9, Runx2, or Snail. (I) Proposed regulatory mechanism to inhibit tumor progression by iTS-CM. According to the mechanism, β -catenin-overexpressing iTS cells secrete ubiquitin C (Ubc), enolase 1 (Eno1), p53, and Trail. They suppress the progression of tumor cells by downregulating MMP9, Runx2, Snail, and PDL1, while upregulating cleaved-caspase 3. It should be noted that Eno1 interacts with CD44 and inhibits MMP9, Runx2, and Snail. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/34373756>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53(R175H) blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma *Scientific Reports* 2023-07-14 [PMID: 37452087] (Western Blot, Mouse)

Haagsma J, Kolendowski B, Buensuceso A et al. Gain-of-function p53 R175H blocks apoptosis in a precursor model of ovarian high-grade serous carcinoma *Research Square* 2023-03-24 (WB)

Feng Y, Liu S, Zha R et al. Prostate cancer-associated urinary proteomes differ before and after prostatectomy *Therapeutic advances in medical oncology* 2022-10-27 [PMID: 36324734] (WB, Human)

Feng Y, Liu S, Zha R, et al. Mechanical Loading-Driven Tumor Suppression Is Mediated by Lrp5-Dependent and Independent Mechanisms *Cancers* 2021-01-13 [PMID: 33450808] (WB, Mouse)

Herzer K, Hofmann TG, Teufel A et al. IFN- α -Induced Apoptosis in Hepatocellular Carcinoma Involves Promyelocytic Leukemia Protein TRAIL Independently of p53. *Cancer Res*;69(3):855-62. 2009-02-01 [PMID: 19141642] (WB, Mouse)





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB500-220

NBL1-17161	TRAIL/TNFSF10 Overexpression Lysate
NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB500-220

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

